Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)

A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of the Fix-dose Combination Therapy With Gemigliptin 50mg and Rosuvastatin 20mg With Type 2 Diabetes and Dyslipidemia

To evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg with type 2 diabetes and dyslipidemia

Inclusion Criteria:

• Type 2 Diabetes Mellitus with Dyslipidemia
• Adults who are at least 19 years old

Exclusion Criteria:

• Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma
• Patients with gestational diabetes or secondary diabetes
• Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring treatment
• Patients with thyroid gland dysfunction deviating from the normal TSH range
• Patients with pituitary insufficiency or adrenal insufficiency